BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38461206)

  • 1. mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.
    Zhang L; Liu P; Zhuang L; Ling S; Zhan Q; Zhou W; Su R; Yin L; Que Q; Hong J; Bao J; Shao C; Cai J; Zheng S; Xu X
    Mol Biomed; 2024 Mar; 5(1):9. PubMed ID: 38461206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
    BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
    Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
    Schnitzbauer AA; Filmann N; Adam R; Bachellier P; Bechstein WO; Becker T; Bhoori S; Bilbao I; Brockmann J; Burra P; Chazoullières O; Cillo U; Colledan M; Duvoux C; Ganten TM; Gugenheim J; Heise M; van Hoek B; Jamieson N; de Jong KP; Klein CG; Klempnauer J; Kneteman N; Lerut J; Mäkisalo H; Mazzaferro V; Mirza DF; Nadalin S; Neuhaus P; Pageaux GP; Pinna AD; Pirenne J; Pratschke J; Powel J; Rentsch M; Rizell M; Rossi G; Rostaing L; Roy A; Scholz T; Settmacher U; Soliman T; Strasser S; Söderdahl G; Troisi RI; Turrión VS; Schlitt HJ; Geissler EK
    Ann Surg; 2020 Nov; 272(5):855-862. PubMed ID: 32889867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma.
    Xu SL; Zhang YC; Wang GY; Yang Q; Liu B; Zhang J; Li H; Wang GS; Yang Y; Chen GH
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):674-681. PubMed ID: 27825633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
    Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
    Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation.
    Wang MX; Chen D; Zhao YY; Yang B; Jiang JP; Zeng FJ; Wei L; Chen ZS
    Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):378-383. PubMed ID: 32622825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
    Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
    World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
    Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
    J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
    Duvoux C; Toso C
    Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
    Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
    Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Grigg SE; Sarri GL; Gow PJ; Yeomans ND
    Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].
    Zhao X; Lu S; Wang M; Wu J; Lin D; Guo Q; Lai W; Zeng D; Li C; Liu Y; Sun L; Yan D; Li N
    Zhonghua Wai Ke Za Zhi; 2014 Apr; 52(4):245-8. PubMed ID: 24924566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.
    Toso C; Merani S; Bigam DL; Shapiro AM; Kneteman NM
    Hepatology; 2010 Apr; 51(4):1237-43. PubMed ID: 20187107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
    Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
    Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
    Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
    Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.
    Menon KV; Hakeem AR; Heaton ND
    Aliment Pharmacol Ther; 2013 Feb; 37(4):411-9. PubMed ID: 23278125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.